{"title":"Drug management of autosomal dominant polycystic kidney disease.","authors":"Thiveya Theivendran, Alister Ramachandran, Gopi Rangan","doi":"10.18773/austprescr.2022.052","DOIUrl":"10.18773/austprescr.2022.052","url":null,"abstract":"<p><p>Autosomal dominant polycystic kidney disease is the most common genetic kidney disease affecting adults. Approximately 60% of patients develop kidney failure by 60 years of age due to slowly expanding kidney cysts. A healthy lifestyle and rigorous control of blood pressure slow kidney cyst growth. These interventions can be effective in reducing progression to kidney failure and cardiovascular disease, especially if started in early adulthood. Tolvaptan, a vasopressin receptor antagonist, slows kidney cyst growth and the decline in the estimated glomerular filtration rate by 1 mL/minute/1.73 m2 per year. It is indicated in patients with chronic kidney disease who are at high risk of progression to kidney failure. Chronic kidney pain is common and can be managed with analgesics, and input from pain specialists if refractory.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/2d/austprescr-45-167.PMC9584797.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Australian PrescriberPub Date : 2022-10-01Epub Date: 2022-10-04DOI: 10.18773/austprescr.2022.063
Matthew Bruorton, Thomas Goddard
{"title":"Drug treatment of cystic fibrosis.","authors":"Matthew Bruorton, Thomas Goddard","doi":"10.18773/austprescr.2022.063","DOIUrl":"https://doi.org/10.18773/austprescr.2022.063","url":null,"abstract":"<p><p>Cystic fibrosis is the most common life-limiting autosomal recessive condition in Australia. A defect in the cystic fibrosis transmembrane conductance regulator protein affects chloride transport across epithelial cells. Patients with cystic fibrosis produce thick sticky mucus. This causes problems in multiple organs, particularly the lungs. Cystic fibrosis modulator therapies can partially correct the underlying pathophysiology and improve chloride transport, thereby improving morbidity. Life expectancy is improving, so many patients are now developing chronic diseases associated with ageing. All health professionals should be aware that the cystic fibrosis modulator therapies are metabolised via cytochrome P450 pathways in the liver. There are therefore significant drug-drug interactions with medicines metabolised by the same pathways.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/cf/austprescr-45-171.PMC9584790.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40705259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Australian PrescriberPub Date : 2022-10-01Epub Date: 2022-10-04DOI: 10.18773/austprescr.2022.062
Vicki Dyson
{"title":"Role of empagliflozin in chronic lithium toxicity.","authors":"Vicki Dyson","doi":"10.18773/austprescr.2022.062","DOIUrl":"https://doi.org/10.18773/austprescr.2022.062","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/96/austprescr-45-158.PMC9584789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.","authors":"Helen K Reddel, Gloria J Foxley, Sharon R Davis","doi":"10.18773/austprescr.2022.033","DOIUrl":"https://doi.org/10.18773/austprescr.2022.033","url":null,"abstract":"<p><p>Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/f8/austprescr-45-125.PMC9427634.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
